Download Otter for your meeting notes

TAME & Biomarker Q&A with Nir Barzilai Institute for Aging Research: Otter Voice Meeting Notes

TAME & Biomarker Q&A with Nir Barzilai Institute for Aging Research

Allison Duettmann1h

Speaker 1

00:00

All right, well, it's really good to see so many. And I'm expecting a lot more folks to join via the waiting room, and I'll be accepting them. I think as we speak, I think we have a really quite fantastic and special and special session ahead of us today, not only because it's almost Thanksgiving, but also because I think near your presentation was much, much, much expected. How many people here in the group? Thank you so much for making time for joining us, I will try to keep my comments brief questions that I'll be asking you up front. And then I'm hoping that people can collect the questions in the chat.

Speaker 2

00:38

So thank you for being such a good leader for us. And it's really good, you know, I really appreciate that somebody, and that's so much younger than me is starting to tell me where to go and what to do. I think it's very much needed. Thanks, thanksgiving for that.

Speaker 1

01:00

Very nice. I'm very humbled. And, and, and, and I, I mean, I'm very much looking forward to you telling us a little bit of where this group may, may go outward, which makes sense. So I'm still accepting a few more folks into the conversation. But I think it would be really lovely to first. Okay, first of all, at the end of the session, I'm going to share with you what I'm hoping to be the program outline for next year. So there's an additional practice stay on even though I don't think that we have problems with people staying on for the session. But that's just an additional point. And then I'll be introducing next week's guest as well. But I think first and foremost, we will just have a q&a with Neil. And I will post the longer BIOS near here in the chat, but to keep it kind of very short and sweet. And near as a professor in the Department of endocrinology, medicine, and the Department of genetics at the Albert Einstein College of Medicine. He's also the Ingeborg and Leon Renner Chair of aging research at that very college. And he's the founding director of the Institute of aging research at that very college, and the director of the Nathan choc Center for Excellence in the basic biology of aging, which is funded by the National Institutes of Health. He's currently leading. And I think that's of interest to many people here in this group, the time trial, which is really a multicenter multicenter study to prove the concept, that multi, multi morbidities of aging can be delayed in humans, and have the very ambitious goal of changing the FDA indications to allow for next generation interventions. So yeah, I'm terribly excited that you're joining us today. I'm going to post your longer bio here in the chat. And feel free to already Ask, ask questions away that I'll be then collecting in the chat. And but for now, I think maybe we could just start with a very simple question, which is, can you tell us a little bit more about a team to bring people up to speed just in case they don't know what it is? And what made your phone table salt?

Speaker 2

03:10

And, okay, let me let me share some slides from time to time just to make a point. And so I want to, I want to first make sure that we're all understanding the challenge. And the challenge is that for every other disease, we do it biological discoveries and, and there are biotech or pharmaceuticals that are trying to develop medicine. And then there are drugs to treat the disease. And by the way, it happens that those bio biotech or those pharmaceuticals are like they want better drugs, other pathway. So they feed back into the biological discoveries, and that's how we have a symbiotic relationship in that where we got stuck is the fact that regulatory bodies around the world certainly the FDA here doesn't recognize aging as something that you can target. And now if the FDA doesn't doesn't recognize a preventable condition, their health care providers don't really need to pay their clients it because you know, they'll say this is this is not a disease, the FDA doesn't recognize it, why would we give them money. And secondly, if that's happened, the pharmaceuticals are not going to jump on and get get those resources from the biotechs and develop better drugs, combination of drugs and other things. In order to accelerate how we treat we treat aging. So this is really how it this is really what happened. That led To design team, how, how do we design a study? And that if it's successful, the FDA will recognize that aging is something that you can be targeted. And just, that's another discussion. But one of the things we found and we went to the Senate and to the Congress, because we thought maybe we have to change the law, because the FDA has diseases that he targets Do we need to call aging a disease? And we found out that we don't know we don't need to call aging a disease. Okay. And I'll tell you what I mean, a later. And so, Ellison there, the question for me, let me stop sharing the question for me is, and we went to the FDA, and we sat with them, and it was documented. It was documented in her Ron Howard film, the age of aging, if you didn't see, it's the best movie about aging. Okay, and I think it'll take a year to get the producer like Ron Howard to do it again. But, Ellison, if you permit me, I'll give it three minutes or four minute clip of us going to the FDA, and they interview with Bob temple, who said Bring it off. Okay. Is it okay?

Unknown Speaker

06:28

Please go ahead. I'd

Speaker 2

06:28

love to see it. Okay, if it's because I think I think people are saying, you know, the FDA doesn't approve does not approve. Let me just show it on record here. Because we think that forming is the first one. But can you see better than Miss forming. And we want to make sure that that's the template, we have that hypothesis

Processing audio...